JP2022518175A5 - - Google Patents
Info
- Publication number
- JP2022518175A5 JP2022518175A5 JP2021540023A JP2021540023A JP2022518175A5 JP 2022518175 A5 JP2022518175 A5 JP 2022518175A5 JP 2021540023 A JP2021540023 A JP 2021540023A JP 2021540023 A JP2021540023 A JP 2021540023A JP 2022518175 A5 JP2022518175 A5 JP 2022518175A5
- Authority
- JP
- Japan
- Prior art keywords
- xrpd pattern
- solid form
- form according
- approximately
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790342P | 2019-01-09 | 2019-01-09 | |
| US62/790,342 | 2019-01-09 | ||
| PCT/US2020/012687 WO2020146463A1 (en) | 2019-01-09 | 2020-01-08 | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518175A JP2022518175A (ja) | 2022-03-14 |
| JP2022518175A5 true JP2022518175A5 (cg-RX-API-DMAC7.html) | 2023-01-24 |
| JP7483722B2 JP7483722B2 (ja) | 2024-05-15 |
Family
ID=69467745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540023A Active JP7483722B2 (ja) | 2019-01-09 | 2020-01-08 | (s)-4-(4-(4-(((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-4-イル)オキシ)メチル)ベンジル)ピペラジン-1-イル)-3-フルオロベンゾニトリルを含む固体形態及びその塩、ならびにそれらを含む組成物及びその使用方法 |
Country Status (23)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| EP4095132A1 (en) * | 2020-01-20 | 2022-11-30 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| CN120004860A (zh) * | 2020-07-20 | 2025-05-16 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
| KR20240013793A (ko) | 2021-05-27 | 2024-01-30 | 셀진 코포레이션 | 조합 요법을 사용하는 다발성 골수종의 치료 방법 |
| TW202606669A (zh) * | 2024-05-30 | 2026-02-16 | 美商西建公司 | Arnt降解化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CA3010794A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| IL278854B2 (en) * | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| PL3796912T3 (pl) * | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
-
2020
- 2020-01-08 EP EP20703618.7A patent/EP3908582B1/en active Active
- 2020-01-08 ES ES20703618T patent/ES3059967T3/es active Active
- 2020-01-08 EA EA202191620A patent/EA202191620A1/ru unknown
- 2020-01-08 SI SI202030713T patent/SI3908582T1/sl unknown
- 2020-01-08 AU AU2020206694A patent/AU2020206694B2/en active Active
- 2020-01-08 IL IL284680A patent/IL284680B1/en unknown
- 2020-01-08 CN CN202080019069.2A patent/CN113597425A/zh active Pending
- 2020-01-08 FI FIEP20703618.7T patent/FI3908582T3/fi active
- 2020-01-08 US US16/737,739 patent/US11370777B2/en active Active
- 2020-01-08 KR KR1020217025072A patent/KR102875111B1/ko active Active
- 2020-01-08 CA CA3125756A patent/CA3125756A1/en active Pending
- 2020-01-08 HR HRP20260065TT patent/HRP20260065T1/hr unknown
- 2020-01-08 CN CN202410399193.6A patent/CN118324742A/zh active Pending
- 2020-01-08 PT PT207036187T patent/PT3908582T/pt unknown
- 2020-01-08 WO PCT/US2020/012687 patent/WO2020146463A1/en not_active Ceased
- 2020-01-08 MX MX2021008295A patent/MX2021008295A/es unknown
- 2020-01-08 BR BR112021013435-2A patent/BR112021013435A2/pt not_active Application Discontinuation
- 2020-01-08 PL PL20703618.7T patent/PL3908582T3/pl unknown
- 2020-01-08 SG SG11202107439XA patent/SG11202107439XA/en unknown
- 2020-01-08 JP JP2021540023A patent/JP7483722B2/ja active Active
- 2020-01-08 CN CN202210010514.XA patent/CN114394954B/zh active Active
- 2020-01-08 EP EP25213779.9A patent/EP4725553A3/en active Pending
- 2020-01-08 DK DK20703618.7T patent/DK3908582T3/da active
- 2020-01-08 RS RS20260055A patent/RS67646B1/sr unknown
- 2020-01-08 LT LTEPPCT/US2020/012687T patent/LT3908582T/lt unknown
- 2020-01-08 SM SM20260018T patent/SMT202600018T1/it unknown
-
2022
- 2022-05-27 US US17/827,491 patent/US12391672B2/en active Active
-
2025
- 2025-07-16 US US19/271,096 patent/US20250340536A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014259431B2 (en) | Derivatives of dolastatin 10 and auristatins | |
| JP2020511461A5 (cg-RX-API-DMAC7.html) | ||
| TW200817346A (en) | Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners | |
| JP2024516371A5 (cg-RX-API-DMAC7.html) | ||
| JP2013532668A5 (cg-RX-API-DMAC7.html) | ||
| JP2014503574A5 (cg-RX-API-DMAC7.html) | ||
| JP2010526145A5 (cg-RX-API-DMAC7.html) | ||
| US10047060B2 (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
| JP2017515844A5 (cg-RX-API-DMAC7.html) | ||
| CA2516370A1 (en) | A process of preparing imatinib and imatinib prepared thereby | |
| JP2014516360A5 (cg-RX-API-DMAC7.html) | ||
| JP2005511698A5 (cg-RX-API-DMAC7.html) | ||
| JP2019502708A5 (cg-RX-API-DMAC7.html) | ||
| PE20251236A1 (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| JP2020511536A5 (cg-RX-API-DMAC7.html) | ||
| RU2013143381A (ru) | Фармацевтически приемлемая соль (е)-n-[4-[[3-хлор-4-(2-пиридилметокси)фенил]амино]-3-циано-7-этокси-6-хинолил]3-[(2r)-1-метилпирролидин-2-ил]проп-2-енамида, способ ее получения и ее медицинское применение | |
| JP2018529690A5 (cg-RX-API-DMAC7.html) | ||
| EP2895478B1 (en) | Triazole carboxamide derivatives | |
| JP2022535613A (ja) | 新規なアミノアルカン酸にビフェニル基を導入した誘導体化合物、およびこれを含む抗真菌薬学的組成物 | |
| JP2022507795A5 (cg-RX-API-DMAC7.html) | ||
| CA2667041A1 (en) | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression | |
| JP2006512321A5 (cg-RX-API-DMAC7.html) | ||
| JP2020517676A5 (cg-RX-API-DMAC7.html) | ||
| JP2008503575A5 (cg-RX-API-DMAC7.html) | ||
| JP2022525102A5 (cg-RX-API-DMAC7.html) |